Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

USDA donates funds for teaching food safety awareness to AIDS patients

USDA donates funds for teaching food safety awareness to AIDS patients

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck to launch Sabril in the US following FDA's NDA approval

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

e-infrastructure to tackle diseases

e-infrastructure to tackle diseases

Novel genome-analysis strategy to speed search for gene-disease links

Novel genome-analysis strategy to speed search for gene-disease links

Research on blood transfusions points to a potential risk of transfusing donated platelets

Research on blood transfusions points to a potential risk of transfusing donated platelets

Proteomics helps find key to keeping cells in shape

Proteomics helps find key to keeping cells in shape

Less is more when it comes to blood transfusions

Less is more when it comes to blood transfusions

Epigenetic alterations may serve as markers for chronic leukemia

Epigenetic alterations may serve as markers for chronic leukemia

Health-related quality of life in chronic kidney disease patients

Health-related quality of life in chronic kidney disease patients

Study of pulmonary hypertension treatment in sickle cell patients stopped by NHLBI

Study of pulmonary hypertension treatment in sickle cell patients stopped by NHLBI

Anemia increases risk of death in people aged 85 and older

Anemia increases risk of death in people aged 85 and older

Hepatitis C infection:  Treatment options equally effective, likelihood of success known early on

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

New hope for the global iron deficiency problem

New hope for the global iron deficiency problem

Xerostomia linked to use of multiple medications

Xerostomia linked to use of multiple medications

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.